MS
Mesoblast Limited
MSB.AX · ASX
$2.39 +0.42% (+$0.01)
1M +6.73%
Market Cap $2.22B
P/E Ratio -
Div. Yield -
ROE 16.10%
Piotroski F-Score Moderate
4/9Valuation
26 /100
Expensive P/B 3.87x
P/S 33.99x
EV/FFO N/A
Growth
88 /100
Growing Book val. growth 4.24%
Rev. growth 153.98%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 223.08%
Gross margin 53.34%
FCF margin 80.33%
Quality
1 /100
Poor ROA 12.06%
ROIC 20.29%
Asset turnover 0.08x
Debt
93 /100
Low Current ratio 1.58x
Debt/Equity 0.24x
Debt/Assets N/A
Stability
48 /100
Moderate EPS volatility 24.98%
Beta 0.82x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o MSB.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Silviu Itescu
Employees
108
Headquarters
Melbourne
Prihajajoči dogodki
04 MAR.
Earnings
Upcoming earnings report